RU2747877C2 - Аналоги эфр(а) с заместителями - жирными кислотами - Google Patents

Аналоги эфр(а) с заместителями - жирными кислотами Download PDF

Info

Publication number
RU2747877C2
RU2747877C2 RU2018127882A RU2018127882A RU2747877C2 RU 2747877 C2 RU2747877 C2 RU 2747877C2 RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A RU2018127882 A RU 2018127882A RU 2747877 C2 RU2747877 C2 RU 2747877C2
Authority
RU
Russia
Prior art keywords
egf
ethoxy
peptide
amino
amino acid
Prior art date
Application number
RU2018127882A
Other languages
English (en)
Russian (ru)
Other versions
RU2018127882A3 (https=
RU2018127882A (ru
Inventor
Дзяньхэ ЧЕН
Йеспер Ф. ЛАУ
Янош Тибор КОДРА
Биргит ВЕЧОРЕК
Ларс ЛИНДЕРОТ
Хеннинг ТЁГЕРСЕН
Салька Эльбёль РАСМУССЕН
Патрик Уилльям ГЭРИБЭЙ
Original Assignee
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ново Нордиск А/С filed Critical Ново Нордиск А/С
Publication of RU2018127882A publication Critical patent/RU2018127882A/ru
Publication of RU2018127882A3 publication Critical patent/RU2018127882A3/ru
Application granted granted Critical
Publication of RU2747877C2 publication Critical patent/RU2747877C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2018127882A 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами RU2747877C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CN2016076580 2016-03-17
CNPCT/CN2016/076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (3)

Publication Number Publication Date
RU2018127882A RU2018127882A (ru) 2020-02-13
RU2018127882A3 RU2018127882A3 (https=) 2020-06-19
RU2747877C2 true RU2747877C2 (ru) 2021-05-17

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127882A RU2747877C2 (ru) 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами

Country Status (26)

Country Link
US (2) US10822385B2 (https=)
EP (1) EP3402811B1 (https=)
JP (2) JP6797926B2 (https=)
KR (1) KR102417487B1 (https=)
CN (1) CN108473550B (https=)
AU (1) AU2017207862B2 (https=)
BR (1) BR112018013820A2 (https=)
CA (1) CA3010756A1 (https=)
CL (1) CL2018001868A1 (https=)
CO (1) CO2018007440A2 (https=)
DK (1) DK3402811T3 (https=)
ES (1) ES2916998T3 (https=)
HR (1) HRP20220720T1 (https=)
HU (1) HUE058647T2 (https=)
IL (1) IL260043A (https=)
LT (1) LT3402811T (https=)
MX (1) MX2018008681A (https=)
MY (1) MY195199A (https=)
PE (1) PE20181376A1 (https=)
PH (1) PH12018501502A1 (https=)
PL (1) PL3402811T3 (https=)
RS (1) RS63298B1 (https=)
RU (1) RU2747877C2 (https=)
SA (1) SA518391996B1 (https=)
SI (1) SI3402811T1 (https=)
WO (1) WO2017121850A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402784T1 (sl) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
WO2020070276A1 (en) 2018-10-05 2020-04-09 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and egf(a) peptides
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
AU2020326265A1 (en) 2019-08-07 2022-02-03 Novo Nordisk A/S Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641275A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4076492A4 (en) 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296694A2 (en) * 2008-04-23 2011-03-23 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
RU2528735C2 (ru) * 2008-09-12 2014-09-20 Ринат Ньюросайенс Корпорейшн Антагонисты pcsk9

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103052900A (zh) 2010-08-02 2013-04-17 日本电气株式会社 偏振器和发光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
JP2015533483A (ja) 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
EP2986313B1 (en) * 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
US20180207223A1 (en) * 2015-03-19 2018-07-26 Institut De Cardiologie De Montreal Pcsk9 inhibitory polypolypeptides and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296694A2 (en) * 2008-04-23 2011-03-23 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
RU2528735C2 (ru) * 2008-09-12 2014-09-20 Ринат Ньюросайенс Корпорейшн Антагонисты pcsk9
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHAN L. et al. PCSK9 Binds to Multiple Receptors and Can Be Functionally Inhibited by an EGF-A Peptide; Biochem.&Biophys.Comm., 2008, v.375, n.1, p.69-73. *
ZHANG Y. et al. Calcium-independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain; J.Mol.Bio., 2012, v.422, p.685-696. *

Also Published As

Publication number Publication date
CN108473550A (zh) 2018-08-31
AU2017207862A1 (en) 2018-07-05
DK3402811T3 (da) 2022-06-13
US20200407409A1 (en) 2020-12-31
JP6797926B2 (ja) 2020-12-09
PE20181376A1 (es) 2018-09-05
WO2017121850A1 (en) 2017-07-20
PL3402811T3 (pl) 2022-07-11
EP3402811A1 (en) 2018-11-21
JP2019505521A (ja) 2019-02-28
EP3402811B1 (en) 2022-03-30
KR20180100177A (ko) 2018-09-07
RS63298B1 (sr) 2022-07-29
CN108473550B (zh) 2022-11-22
PH12018501502A1 (en) 2019-03-25
US10822385B2 (en) 2020-11-03
US20190016768A1 (en) 2019-01-17
MY195199A (en) 2023-01-11
KR102417487B1 (ko) 2022-07-06
CO2018007440A2 (es) 2018-09-28
RU2018127882A3 (https=) 2020-06-19
IL260043A (en) 2018-07-31
RU2018127882A (ru) 2020-02-13
MX2018008681A (es) 2018-09-17
SI3402811T1 (sl) 2022-06-30
SA518391996B1 (ar) 2021-07-14
HRP20220720T1 (hr) 2022-09-30
LT3402811T (lt) 2022-06-10
ES2916998T3 (es) 2022-07-06
HUE058647T2 (hu) 2022-09-28
CA3010756A1 (en) 2017-07-20
BR112018013820A2 (pt) 2018-12-11
CL2018001868A1 (es) 2018-08-31
AU2017207862B2 (en) 2020-12-17
JP2021035989A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
RU2747877C2 (ru) Аналоги эфр(а) с заместителями - жирными кислотами
KR102379958B1 (ko) Gip 유도체 및 이의 용도
CN104311657B (zh) 双酰化glp-1衍生物
JP6352806B2 (ja) 新規のグルカゴン類似体
US11649269B2 (en) Bifunctional compounds comprising insulin peptides and EGF(A) peptides
EA020326B1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CN101005857A (zh) 多肽延长标记
AU2012234276A1 (en) Novel glucagon analogues
US20200165313A1 (en) Egf(a) analogues, preparation, formulations and uses thereof
JP2020528049A (ja) 二機能性化合物
HK1262866B (en) Egf(a) analogues with fatty acid substituents